Payment overview · 2025
General Payments
$170.97
9 reported records · 4 companies
Healthcare provider profile · identity verified
Donald Smith, DO
Allopathic & Osteopathic Physicians|Family Medicine · OKOLONA, MS · NPI 1386600427
Verified facts
What the public records show
CMS Open Payments records show Donald Smith, DO received $170.97 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 47.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.43 | 47.0% | 4 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $55.10 | 32.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.33 | 11.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.11 | 9.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $170.97 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $80.43 | 4 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $55.10 | 3 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $55.10 | 3 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $55.10 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.69 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 277 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 88 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
277 | 52 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
88 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 910 | 233 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 805 | 237 |
| Amlodipine Besylate | Amlodipine Besylate | 768 | 205 |
| Carvedilol | Carvedilol | 586 | 144 |
| Atorvastatin Calcium | Atorvastatin Calcium | 570 | 154 |
| Tizanidine Hcl | Tizanidine Hcl | 492 | 138 |
| Potassium Chloride | Potassium Chloride | 466 | 121 |
| Pantoprazole Sodium | Pantoprazole Sodium | 441 | 112 |
| Famotidine | Famotidine | 429 | 120 |
| Fluticasone Propionate | Fluticasone Propionate | 399 | 165 |
| Omeprazole | Omeprazole | 397 | 111 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 391 | 117 |
| Metformin Hcl | Metformin Hcl | 385 | 101 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 384 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 81 |
| Dexamethasone | Dexamethasone | 318 | 198 |
| Metoprolol Succinate | Metoprolol Succinate | 307 | 77 |
| Lisinopril | Lisinopril | 300 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 298 | 80 |
| Montelukast Sodium | Montelukast Sodium | 295 | 85 |
| Clonidine Hcl | Clonidine Hcl | 294 | 94 |
| Ibuprofen | Ibuprofen | 291 | 71 |
| Zolpidem Tartrate | Zolpidem Tartrate | 291 | 54 |
| Allopurinol | Allopurinol | 282 | 72 |
| Ozempic | Semaglutide | 277 | 52 |
| Metformin Hcl Er | Metformin Hcl | 275 | 73 |
| Furosemide | Furosemide | 266 | 90 |
| Losartan Potassium | Losartan Potassium | 259 | 60 |
| Diclofenac Sodium | Diclofenac Sodium | 242 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 232 | 59 |
| Meloxicam | Meloxicam | 226 | 61 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 217 | 56 |
| Alprazolam | Alprazolam | 205 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 197 | 46 |
| Buspirone Hcl | Buspirone Hcl | 196 | 56 |
| Trazodone Hcl | Trazodone Hcl | 196 | 43 |
| Tramadol Hcl | Tramadol Hcl | 189 | 47 |
| Eliquis | Apixaban | 188 | 38 |
| Azithromycin | Azithromycin | 184 | 145 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 179 | 61 |
| Simvastatin | Simvastatin | 178 | 46 |
| Fluconazole | Fluconazole | 176 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 47 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 154 | 38 |
| Baclofen | Baclofen | 152 | 46 |
| Donepezil Hcl | Donepezil Hcl | 151 | 38 |
| Atenolol | Atenolol | 150 | 43 |
| Amitriptyline Hcl | Amitriptyline Hcl | 147 | 37 |
| Clonazepam | Clonazepam | 144 | 22 |
| Pregabalin | Pregabalin | 138 | 33 |
| Estradiol | Estradiol | 131 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 131 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 130 | 57 |
| Meclizine Hcl | Meclizine Hcl | 124 | 41 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 122 | 26 |
| Irbesartan | Irbesartan | 118 | 29 |
| Linzess | Linaclotide | 117 | 33 |
| Valsartan | Valsartan | 113 | 34 |
| Mupirocin | Mupirocin | 112 | 71 |
| Amoxicillin | Amoxicillin | 111 | 73 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 110 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 107 | 39 |
| Torsemide | Torsemide | 107 | 33 |
| Synthroid | Levothyroxine Sodium | 104 | 22 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 102 | 33 |
| Prednisone | Prednisone | 102 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 33 |
| Mirtazapine | Mirtazapine | 99 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 98 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 24 |
| Ondansetron Odt | Ondansetron | 94 | 43 |
| Promethazine Hcl | Promethazine Hcl | 92 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 23 |
| Rybelsus | Semaglutide | 88 | 18 |
| Celecoxib | Celecoxib | 87 | 25 |
| Ezetimibe | Ezetimibe | 87 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 23 |
| Levetiracetam | Levetiracetam | 80 | 22 |
| Lovastatin | Lovastatin | 76 | 12 |
| Valacyclovir | Valacyclovir Hcl | 76 | 27 |
| Clindamycin Hcl | Clindamycin Hcl | 74 | 41 |
| Acyclovir | Acyclovir | 72 | 24 |
| Bupropion Xl | Bupropion Hcl | 71 | 21 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 71 | 27 |
| Spironolactone | Spironolactone | 71 | 23 |
| Colchicine | Colchicine | 70 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 70 | 31 |
| Tresiba Flextouch U-200 | Insulin Degludec | 70 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 57 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 19 |
| Topiramate | Topiramate | 67 | 14 |
| Sucralfate | Sucralfate | 64 | 15 |
| Chlorthalidone | Chlorthalidone | 63 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | 18 |
| Farxiga | Dapagliflozin Propanediol | 62 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 61 | 50 |
| Methocarbamol | Methocarbamol | 60 | 27 |
| Mometasone Furoate | Mometasone Furoate | 59 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 16 |
| Warfarin Sodium | Warfarin Sodium | 57 | 13 |
| Jardiance | Empagliflozin | 55 | 22 |
| Levofloxacin | Levofloxacin | 55 | 37 |
| Lorazepam | Lorazepam | 55 | 12 |
| Zaleplon | Zaleplon | 55 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 48 | suppressed |
| Trulicity | Dulaglutide | 48 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 48 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | 13 |
| Nitroglycerin | Nitroglycerin | 46 | 24 |
| Benazepril Hcl | Benazepril Hcl | 45 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 45 | suppressed |
| Glimepiride | Glimepiride | 44 | suppressed |
| Naproxen | Naproxen | 43 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 43 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 42 | 12 |
| Eszopiclone | Eszopiclone | 41 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 40 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Dutasteride | Dutasteride | 38 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | 14 |
| Azelastine Hcl | Azelastine Hcl | 37 | 18 |
| Nystatin | Nystatin | 37 | 14 |
| Cilostazol | Cilostazol | 36 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 12 |
| Ramipril | Ramipril | 34 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 33 | 11 |
| Risperidone | Risperidone | 33 | suppressed |
| Cefadroxil | Cefadroxil | 32 | 26 |
| Cephalexin | Cephalexin | 31 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 26 |
| Novolog Flexpen | Insulin Aspart | 29 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 24 |
| Diazepam | Diazepam | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 25 | 17 |
| Digoxin | Digoxin | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 23 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Pentoxifylline | Pentoxifylline | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Carbamazepine Er | Carbamazepine | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 18 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 18 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 13 |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Cytomel | Liothyronine Sodium | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Norethindrone | Norethindrone | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Misoprostol | Misoprostol | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $170.97 · 9 records | Novo Nordisk Inc | BREZTRI, Flector, Licart, Ozempic, Rybelsus, Tirosint, VOQUEZNA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error